Navigation Links
Enzyme Replacement May Help in Fabry Disease
Date:12/2/2009

Whether treatment prolongs life remains unclear, researchers say

WEDNESDAY, Dec. 2 (HealthDay News) -- New research suggests that enzyme replacement therapy can make a major difference in the lives of people with Fabry disease, a rare illness that affects the kidneys, heart and brain.

The progressive disease, linked to the lack of an enzyme that helps metabolic pathways function in the body, can be fatal because it boosts the risk for a stroke, heart attack and kidney disease.

A study published Dec. 1 in The Lancet analyzed a treatment that replaced an enzyme called agalsidase alfa.

The researchers found that the treatment reduced signs of heart disease in people who had oversized hearts. It also appeared to improve kidney function, lower pain levels and improve scores on quality-of-life surveys.

"Enzyme-replacement therapy has only been available typically since 2001, and, thus, duration of exposure might be too short to assess whether this strategy prolongs life," the researchers wrote in an accompanying commentary. Whether the treatment, which they described as costly, helps people live longer needs confirmation, they noted.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more on Fabry disease.



-- Randy Dotinga



SOURCE: The Lancet, news release, Dec. 1, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Particles Detected in Vials from Genzymes Plant Not Expected to Impact Aldurazyme or Naglazyme
2. Reportlinker Adds Boosting Immunity Through Digestion: The Relation Among Probiotics, Prebiotics and Digestive Enzymes
3. Genetic variation of enzyme linked with outcomes for women receiving tamoxifen
4. Enzyme is key to clogged arteries
5. Weight-Loss Enzyme Identified
6. LSUHSC research identifies enzyme that makes survival molecule for key vision cells
7. Verenium and Add Food Service GmbH Announce Commercial Distribution Partnership for Fuelzyme(R) and Veretase(TM) Enzymes
8. Lung Enzyme Both Friend and Foe
9. High Activity, Plant Based Diamine Oxidase Enzyme Introduced by Bio-Research Products
10. Video: CREON(R) (Pancrelipase) Delayed-Release Capsules First and Only Pancreatic Enzyme Product to Receive FDA Approval Under New Guidelines
11. Reversing effects of altered enzyme may fight brain tumor growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... ... Elizabeth Murray has always loved walking one to two miles a day. She ... one on her arm. But she got to the point where she could barely ... The valves of the heart wouldn’t close properly resulting in mitral regurgitation, where blood ...
(Date:5/3/2016)... ... 2016 , ... Empyrean Benefit Solutions, Inc., the Hi-Touch Benefits ... in La Vergne, Tennessee, near Nashville. The new center will complement Empyrean’s existing ... services. , “Our Nashville-area center allows us to achieve several goals,” said Richard ...
(Date:5/3/2016)... ... 2016 , ... Ogawa World USA introduced the first of its kind ... Smart Application. The Smart 3D combines the best in technological advancement, design, and massage ... and specialized massage program, each user has a tailored experience unparalleled by any other ...
(Date:5/3/2016)... ... , ... Dr. Poneh Ghasri, cosmetic dentist in West Hollywood , is ... patients. Cosmetic dentistry allows patients to improve the aesthetics of their smiles. These treatments ... or more serious cosmetic flaws. These specials allow patients to achieve their dream smiles ...
(Date:5/3/2016)... ... ... Finding the right way to address a patient’s condition before it worsens will ultimately lower ... , “You do the right thing, at the right time, at the right dose with ... Leonard M. Fromer, MD, FAAFP, from Group Practice Forum. “Even if the cost of the ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... , May 2, 2016 Kalorama Information noted ... Medical Records) market in a recent white paper.  The ... Increased physician usage, a growing market are among the ... in Kalorama,s report EMR 2016: The Market ... Kalorama,s seventh complete study of the EMR industry, and ...
(Date:5/2/2016)... , May 2, 2016  Celsion Corporation (NASDAQ: ... today announced data from the first cohort of ... trial (the OVATION Study) combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  In the first three patients ...
(Date:4/29/2016)... , April 29, 2016 ... for Life Sciences, Product Development Capabilities in ... Science Customer Base . Indegene ... today announced the acquisition of Skura Corporation,s life ... leader in adaptive sales enablement technology for life ...
Breaking Medicine Technology: